Redwood City, California, – Autonomic Technologies, Inc. (ATI) announces the appointment of Karl Schweitzer to the position of Chief Commercialization Officer. In this new role, Mr. Schweitzer will lead the company’s global sales and marketing efforts, bringing innovative therapies to physicians and their patients who suffer from severe and disabling headaches.
Mr. Schweitzer has more than 25 years experience in the field of medical devices. For the past nine years, Mr. Schweitzer was Vice President at Medtronic. Most recently he was Member of the Global Leadership Team of the company’s $2 billion neuromodulation business. During his tenure as Vice President and International General Manager, Medtronic launched the first posture adaptive neurostimulator for pain, the first rechargeable neurostimulator in DBS for movement disorders, obtained approval for several new indications and expanded its direct presence in international markets. Prior to that role Mr. Schweitzer served as Vice President for the company’s Cardiac Surgery division. He came to Medtronic from Boston Scientific, where he was Vice President for the Central and Eastern European region. Previously he held senior leadership roles at Eli Lilly’s Medical Devices division, which later became Guidant.
“Karl brings an impressive track record of driving growth at multinational medical device companies that have consistently maintained their leading positions in their markets,” said Ben Pless, President and Chief Executive Officer of ATI. "We are pleased to have such an accomplished executive join ATI, and we look forward to continued growth under his capable leadership."
Mr. Schweitzer received his Master of Business Administration degree from INSEAD in Fontainebleau, Doctor of Law degree from the University of Vienna, and Master in Business Informatics degree from the Vienna University of Economics and Business.
About Autonomic Technologies
Autonomic Technologies, Inc. (ATI) is a medical device company that develops and commercializes innovative therapies for the treatment of severe headache. The company’s initial product, the ATI™ Neurostimulation System, is CE marked in Europe for the treatment of cluster headache. The system is currently being investigated in a multi-center, randomized study for the treatment of high frequency, high disability migraine.
The ATI Neurostimulation System was voted #2 among the Cleveland Clinic’s top 10 medical innovations for 2013 and was chosen to receive a 2013 Best of What’s New Award from Popular Science in the Health category. ATI was named one of FierceMedicalDevices’ 2012 Fierce 15 most promising privately held medical device and diagnostics companies in the world.
ATI is headquartered in the San Francisco Bay Area and is backed by blue chip investors Kleiner Perkins Caufield and Byers, InterWest Partners, Versant Ventures, Novartis Ventures, Aberdare Ventures, and the Cleveland Clinic. For more information, visit www.ati-spg.com.
Help employers find you! Check out all the jobs and post your resume.
